In July 2026, Johnson & Johnson announced FDA approval for its Dual Energy Thermocool Smarttouch SF (DE STSF) platform—a cardiac ablation catheter that allows physicians to switch between radiofrequency and pulsed field energy within a single device. J&J stated that first U.S. procedures are expected to begin in summer 2026 as the company initiates a phased commercial rollout. For electrophysiology and cardiovascular device sales professionals, the approval is another move in a competitive PFA market—and a potential source of field hiring and training demand.
What was approved
- Dual Energy Thermocool Smarttouch SF platform for cardiac ablation
- Ability to switch between RF and pulsed field energy in one catheter
- Built on the Thermocool Smarttouch SF platform integrated with J&J’s Carto mapping system
- CE mark preceded U.S. approval; European cases began in 2025 per company statements
Why it matters commercially
Pulsed field ablation disrupted EP share in recent years. J&J has publicly emphasized regaining PFA momentum and launching new EP catheters through the decade. Dual-energy workflows may reduce catheter swaps and case time—selling points field teams will need to articulate credibly to electrophysiologists and hospital committees.
Career signals for reps and candidates
- EP and cardio device lanes may see training-heavy hiring during rollout
- Competitive selling intensifies versus Boston Scientific, Medtronic, and other PFA players
- Clinical specialist and proctoring roles often precede full territory expansion
- Candidates should study RF vs PFA tradeoffs—not just headline news